Valuation: Kamada Ltd.

Market Cap 123.56Cr 0 41Cr 36Cr 33Cr 30Cr 57Cr 3.93TCr 58Cr 390.9Cr 153.39Cr 1.97TCr 154.69Cr 151.31Cr 6.55TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 123.56Cr 0 41Cr 36Cr 33Cr 30Cr 57Cr 3.93TCr 58Cr 390.9Cr 153.39Cr 1.97TCr 154.69Cr 151.31Cr 6.55TCr EV / Sales 2026 *
2.06x
EV / Sales 2027 * 1.89x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/07/2015
Director of Finance/CFO 55 31/12/2017
Chief Operating Officer 53 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.04% - - 41Cr
+2.32%+5.24%+46.35%+0.75% 7.83TCr
+0.84%+5.66%-0.15%+27.88% 5.11TCr
+0.90%+1.67%+20.63%+176.54% 4.92TCr
+1.72%+9.27%-48.46%-48.80% 4.47TCr
-0.35%+2.61%+61.78%-23.04% 3.07TCr
+1.45%+2.91%+53.91%+86.05% 2.44TCr
+0.27%+7.93%+133.65%-40.66% 2.36TCr
+2.58%+12.23%+6.63%+202.17% 2.1TCr
-0.62%+3.30%+64.98%+114.68% 1.66TCr
Average +0.93%+3.74%+37.70%+55.06% 3.78TCr
Weighted average by Cap. +1.30%+3.83%+29.62%+42.91%

Financials

2026 *2027 *
Net sales 60Cr 0 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 189.89Cr 75Cr 954.86Cr 75Cr 74Cr 3.18TCr 65Cr 0 22Cr 19Cr 18Cr 16Cr 30Cr 2.08TCr 31Cr 207.07Cr 81Cr 1.04TCr 82Cr 80Cr 3.47TCr
Net income 7.39Cr 0 2.46Cr 2.13Cr 1.99Cr 1.82Cr 3.43Cr 234.96Cr 3.49Cr 23Cr 9.17Cr 117.54Cr 9.25Cr 9.05Cr 391.48Cr 11Cr 0 3.51Cr 3.04Cr 2.84Cr 2.6Cr 4.9Cr 335.23Cr 4.98Cr 33Cr 13Cr 167.71Cr 13Cr 13Cr 558.56Cr
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-